Aevi Genomic Medicine (GNMX) Short Interest Ratio & Short Volume

Short interest is the volume of Aevi Genomic Medicine shares that have been sold short but have not yet been closed out or covered. As of January 31st, traders have sold 338,700 shares of GNMX short. 0.62% of Aevi Genomic Medicine's shares are currently sold short. Learn More on Aevi Genomic Medicine's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.62% of Aevi Genomic Medicine's floating shares are currently sold short.

Aevi Genomic Medicine saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 338,700 shares, an increase of 28.7% from the previous total of 263,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Aevi Genomic Medicine currently has issued a total of 77,714,000 shares. Some of Aevi Genomic Medicine's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aevi Genomic Medicine currently has a public float of 54,380,000 shares.

0.62% of Aevi Genomic Medicine's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Aevi Genomic Medicine: Century Therapeutics, Inc. (5.94%), Adverum Biotechnologies, Inc. (14.03%), Atara Biotherapeutics, Inc. (10.93%), bluebird bio, Inc. (2.91%), Aligos Therapeutics, Inc. (13.10%), Scilex Holding (7.07%), Estrella Immunopharma, Inc. (0.11%), Pluri Inc. (0.82%), MiNK Therapeutics, Inc. (1.21%), Coeptis Therapeutics Holdings, Inc. (0.92%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Netflix, Inc. ($7.24 billion), Charter Communications, Inc. ($4.67 billion), Microchip Technology Incorporated ($3.34 billion), The Charles Schwab Corporation ($2.53 billion), Match Group Inc. ($2.07 billion), Carvana Co. ($1.86 billion), Omnicom Group Inc. ($1.86 billion), Snap Inc. ($1.75 billion), Zillow Group, Inc. ($1.75 billion), and Tiffany & Co. ($1.73 billion). View all of the most shorted stocks.

Short selling GNMX is an investing strategy that aims to generate trading profit from Aevi Genomic Medicine as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Aevi Genomic Medicine occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GNMX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GNMX, twice per month. The most recent reporting period available is January, 31 2020.